Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in a virtual fireside chat at the UBS Biotech Management Live Call Series.
The event, focused on achondroplasia and growth disorders, will take place on July 25, 2025, at 11 am ET. Key participants include CEO Todd Harris, CMO Doug Warner, MD, and CFO Alan Fuhrman, with UBS SMID Cap Biotechnology Analyst Ellie Merle hosting the discussion.
Tyra Biosciences (Nasdaq: TYRA), un'azienda biotech in fase clinica specializzata in farmaci di precisione per il recettore del fattore di crescita dei fibroblasti (FGFR), ha annunciato la sua partecipazione a una chiacchierata virtuale durante la serie di incontri UBS Biotech Management Live Call.
L'evento, incentrato su acondroplasia e disturbi della crescita, si terr脿 il 25 luglio 2025 alle 11:00 ET. Tra i partecipanti principali ci saranno il CEO Todd Harris, il CMO Doug Warner, MD, e il CFO Alan Fuhrman, con l'analista di UBS SMID Cap Biotechnology Ellie Merle che moderer脿 la discussione.
Tyra Biosciences (Nasdaq: TYRA), una empresa biotecnol贸gica en etapa cl铆nica especializada en medicamentos de precisi贸n para el receptor del factor de crecimiento de fibroblastos (FGFR), ha anunciado su participaci贸n en una charla virtual en la serie UBS Biotech Management Live Call.
El evento, centrado en acondroplasia y trastornos del crecimiento, se llevar谩 a cabo el 25 de julio de 2025 a las 11 a.m. ET. Los participantes clave incluyen al CEO Todd Harris, al CMO Doug Warner, MD, y al CFO Alan Fuhrman, con la analista de UBS SMID Cap Biotechnology Ellie Merle como moderadora de la discusi贸n.
Tyra Biosciences (雮橃姢雼�: TYRA)电� 靹湢鞎勳劯韽� 靹膘灔 鞚胳瀽 靾橃毄觳�(FGFR) 鞝曤皜 鞚橃暯頀�鞚� 鞝勲鞙茧 頃樀鐢 鞛勳儊 雼硠 氚旍澊鞓ろ厤 須岇偓搿�, UBS 氚旍澊鞓ろ厤 瓴届榿歆� 霛检澊敫� 旖� 鞁滊Μ歃堨潣 臧�靸� 雽�頇旍棎 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
鞚措矆 頄夓偓电� 鞐瓣敞氍错槙靹膘 氚� 靹膘灔 鞛レ暊毳� 欤检牅搿� 頃橂┌, 2025雲� 7鞗� 25鞚� 鞓れ爠 11鞁� ET鞐� 歆勴枆霅╇媹雼�. 欤检殧 彀戈皜鞛惖鐢 CEO Todd Harris, CMO Doug Warner 氚曥偓, CFO Alan Fuhrman鞚措┌, UBS SMID Cap Biotechnology 鞎犽剱毽姢韸� Ellie Merle臧� 韱犽鞚� 歆勴枆頃╇媹雼�.
Tyra Biosciences (Nasdaq听: TYRA), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les m茅dicaments de pr茅cision ciblant le r茅cepteur du facteur de croissance des fibroblastes (FGFR), a annonc茅 sa participation 脿 une discussion virtuelle dans le cadre de la s茅rie UBS Biotech Management Live Call.
L'茅v茅nement, ax茅 sur l'achondroplasie et les troubles de la croissance, se d茅roulera le 25 juillet 2025 脿 11h00 ET. Les intervenants principaux seront le PDG Todd Harris, le directeur m茅dical Doug Warner, MD, et le directeur financier Alan Fuhrman, avec l'analyste en biotechnologie UBS SMID Cap Ellie Merle animant la discussion.
Tyra Biosciences (Nasdaq: TYRA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf pr盲zisionsmedizinische Therapien f眉r den Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR) spezialisiert hat, hat seine Teilnahme an einem virtuellen Gespr盲ch im Rahmen der UBS Biotech Management Live Call Series angek眉ndigt.
Die Veranstaltung, die sich auf Achondroplasie und Wachstumsst枚rungen konzentriert, findet am 25. Juli 2025 um 11 Uhr ET statt. Zu den Hauptteilnehmern geh枚ren CEO Todd Harris, CMO Doug Warner, MD, und CFO Alan Fuhrman, wobei die UBS SMID Cap Biotechnology Analystin Ellie Merle die Diskussion moderiert.
- None.
- None.
Details of the event are below:
- Title: "Fireside Chat on Achondroplasia and Growth Disorders with Tyra Biosciences"
- TYRA Management: Todd Harris, CEO; Doug Warner, MD, CMO; Alan Fuhrman, CFO
- UBS Host: Ellie Merle, US SMID Cap Biotechnology Analyst, UBS
- Date/Time/Location: Friday, July 25, 2025, 11 am ET, virtual
- Registration link:
About听Tyra Biosciences
Tyra Biosciences, Inc.听(Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SN脜P, enables rapid and precise drug design through iterative molecular SN脜Pshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from听SN脜P, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. TYRA-300's planned clinical development includes three Phase 2 studies: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in听Carlsbad, CA.
For more information about our science, pipeline and people, please visit听www.tyra.bio听and engage with us on听LinkedIn.
Contact:
Amy Conrad
[email protected]
听
View original content to download multimedia:
SOURCE Tyra Biosciences
FAQ
When is Tyra Biosciences (TYRA) presenting at the UBS Biotech Management Live Call Series?
Who will be presenting from Tyra Biosciences (TYRA) at the UBS fireside chat?
What is the focus of Tyra Biosciences' (TYRA) UBS fireside chat presentation?
How can investors access Tyra Biosciences' (TYRA) UBS fireside chat?
